# Wake Robin Validation Comparison Report

*Generated: 2026-01-14 09:47:26*

---

## Enhancement: Clinical Coverage Expansion
- **Baseline**: 13% clinical coverage (41/316 tickers)
- **Enhanced**: 75%+ clinical coverage (238/316 tickers)
- **Method**: Expanded ticker -> sponsor name mapping

## Validation Status

- **Total Test Periods**: 7
- **Baseline Complete**: 7 [DONE]
- **Enhanced Complete**: 7
- **Pending**: 0

## Quarter-by-Quarter Comparison

| Quarter | Screen Date | Q1-Q5 Spread (Before) | Q1-Q5 Spread (After) | Change | Q1 Alpha (Before) | Q1 Alpha (After) | Change |
|---------|-------------|------------------------|----------------------|--------|-------------------|------------------|--------|
| 2023-Q1 | 2023-01-15 | +8.66% | +13.60% | [UP] +4.94% | +12.18% | +16.81% | [UP] +4.63% |
| 2023-Q2 | 2023-04-15 | +3.79% | +7.55% | [UP] +3.76% | +7.66% | +3.99% | [DOWN] -3.67% |
| 2023-Q3 | 2023-07-15 | +12.97% | +9.53% | [DOWN] -3.44% | +5.29% | +2.23% | [DOWN] -3.06% |
| 2023-Q4 | 2023-10-15 | +18.43% | +47.13% | [UP] +28.70% | +12.58% | +17.71% | [UP] +5.13% |
| 2024-Q1 | 2024-01-15 | +13.19% | +8.55% | [DOWN] -4.64% | +19.21% | +4.78% | [DOWN] -14.43% |
| 2024-Q2 | 2024-04-15 | -14.53% | -14.23% | [UP] +0.30% | -2.54% | -0.28% | [UP] +2.26% |
| 2024-Q3 | 2024-07-15 | +22.62% | +10.88% | [DOWN] -11.74% | +29.57% | +13.24% | [DOWN] -16.33% |

## Aggregate Performance

### Average Q1-Q5 Spread
- **Before**: +9.30%
- **After**: +11.86%
- **Improvement**: +2.55% (+27.4%)

### Average Alpha
- **Before**: +11.99%
- **After**: +8.35%
- **Improvement**: -3.64% (-30.3%)

### Success Rate (Positive Spreads)
- **Before**: 6/7 (85.7%)
- **After**: 6/7 (85.7%)

## Improvements by Quarter

### Q1-Q5 Spread Changes:
- **2023-Q4**: +18.43% -> +47.13% (*+28.70% improved*)
- **2023-Q1**: +8.66% -> +13.60% (*+4.94% improved*)
- **2023-Q2**: +3.79% -> +7.55% (*+3.76% improved*)
- **2024-Q2**: -14.53% -> -14.23% (*+0.30% improved*)
- **2023-Q3**: +12.97% -> +9.53% (*-3.44% decreased*)
- **2024-Q1**: +13.19% -> +8.55% (*-4.64% decreased*)
- **2024-Q3**: +22.62% -> +10.88% (*-11.74% decreased*)